#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15366	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2152	708.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1676	1676	T	837	T,C	600,179	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15366	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2152	708.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1410	1410	C	886	C	816	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27938	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3641	765.1	0	.	n	.	0	T695C	SNP	695	695	T	1100	1100	C	860	C,T	801,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27938	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3641	765.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1742	1742	A	966	A	906	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27938	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3641	765.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2376	2376	C	890	C	830	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27938	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3641	765.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2450	2450	A	855	A	811	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27938	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3641	765.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3002	3002	C	825	C	775	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2222	folP	855	855	100.0	folP.l15.c17.ctg.1	1517	145.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1072	1074	AGC	221;226;228	A;G;C	201;204;207	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6216	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3302	187.4	1	SNP	p	S91F	1	.	.	271	273	TTC	512	514	TTC	195;195;193	T;T;C	184;183;183	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6216	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3302	187.4	1	SNP	p	D95G	1	.	.	283	285	GGC	524	526	GGC	200;197;196	G;G;C,T	187;185;183,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6216	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3302	187.4	1	SNP	p	G95N	0	.	.	283	285	GGC	524	526	GGC	200;197;196	G;G;C,T	187;185;183,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1964	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1252	155.7	1	SNP	p	G45D	0	.	.	133	135	GGC	481	483	GGC	255;255;259	G;G,A;C	239;239,1;241	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	872	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1070	81.1	0	.	n	.	0	A197.	DEL	197	197	A	677	677	A	185	A	176	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2963	196.9	1	SNP	p	D86N	0	.	.	256	258	GAC	534	536	GAC	241;244;244	G,C;A;C,T	223,1;219;225,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2963	196.9	1	SNP	p	R87I	0	.	.	259	261	CGT	537	539	CGT	245;243;243	C;G;T	228;225;222	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2963	196.9	1	SNP	p	R87W	0	.	.	259	261	CGT	537	539	CGT	245;243;243	C;G;T	228;225;222	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2963	196.9	1	SNP	p	S87R	1	.	.	259	261	CGT	537	539	CGT	245;243;243	C;G;T	228;225;222	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2963	196.9	1	SNP	p	S88P	0	.	.	262	264	TCC	540	542	TCC	243;245;244	T;C;C	228;229;226	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4704	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2621	178.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1549	1551	GGC	242;239;237	G;G;C	229;227;221	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1248	1250	GCA	218;223;225	G;C;A	203;208;210	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1251	1253	ATC	228;229;229	A;T;C	211;211;211	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1263	1265	GTG	230;228;220	G;T;G	215;208;204	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1263	1265	GTG	230;228;220	G;T;G	215;208;204	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1767	1769	ACC	213;212;209	A;C;C,T	199;200;198,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1821	1823	GCG	190;190;190	G;C,G;G	170;153,2;159	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1821	1823	GCG	190;190;190	G;C,G;G	170;153,2;159	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1944	1946	AGC	171;165;165	A;G;C	154;150;151	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1953	1955	GGC	160;159;157	G;G;C	147;144;143	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4396	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2431	180.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1971	1973	CCG	139;142;141	C,CGGA,CGG;C;G	112,1,1;117;115	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6164	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3209	191.7	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1471	1473	ACG	233;234;230	A;C;G	214;215;212	.	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	6164	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3209	191.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1609	1611	CCG	212;216;213	C;C;G	185;198;193	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2518	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1868	134.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	554	554	C	178	C	160	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	112	91.96	porB1a.l15.c17.ctg.1	483	40.9	0	.	p	.	0	M18T	NONSYN	52	54	ATG	357	359	ACG	96;95;94	A;C;G	85;84;83	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	112	91.96	porB1a.l15.c17.ctg.1	483	40.9	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	399	401	CAA	51;50;50	C;A;A	50;49;48	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	112	91.96	porB1a.l15.c17.ctg.1	483	40.9	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	405	407	TAC	38;35;32	T;A;C	38;35;32	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	501	503	GAA	278;280;277	G,T;A;A	260,1;262;260	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	789	791	GAT	247;248;252	G;A;T	230;230;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	912	914	TCA	238;237;239	T;C;A	222;224;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1041	1043	GTC	241;238;238	G;T;C	229;224;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1053	1055	TCT	243;242;242	T;C;T	231;233;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1371	1373	GCA	248;248;245	G,A;C;A	234,1;233;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	1	SNP	p	G120K	1	.	.	358	360	AAG	747	749	AAG	243;243;243	A;A;G	228;225;225	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	1	SNP	p	A121D	1	.	.	361	363	GAC	750	752	GAC	243;242;244	G;A;C	226;225;227	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3082	porB1b	1047	1047	99.24	porB1b.l6.c4.ctg.1	1734	176.5	1	SNP	p	D121N	0	.	.	361	363	GAC	750	752	GAC	243;242;244	G;A;C	226;225;227	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	392	porB3	990	116	92.24	porB3.l15.c17.ctg.2	467	37.2	0	.	p	.	0	M18T	NONSYN	52	54	ATG	357	359	ACG	82;81;80	A;C;G	74;73;72	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	392	porB3	990	116	92.24	porB3.l15.c17.ctg.2	467	37.2	0	.	p	.	0	T29A	NONSYN	85	87	ACC	390	392	GCC	71;71;68	G;C;C	60;60;58	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	392	porB3	990	116	92.24	porB3.l15.c17.ctg.2	467	37.2	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	399	401	CAA	45;44;44	C;A;A	44;43;42	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	392	porB3	990	116	92.24	porB3.l15.c17.ctg.2	467	37.2	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	405	407	TAC	32;29;26	T;A;C	32;29;26	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10930	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4868	224.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1176	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1025	113.8	1	SNP	p	V57M	1	.	.	169	171	ATG	570	572	ATG	235;236;240	A;T;G	218;218;222	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
